Vardenafil (Levitra/Staxyn) Profile of Super-Responders: Who Gets the Strongest Results

What Makes Vardenafil Different from Other PDE5 Inhibitors

Vardenafil is the most potent PDE5 inhibitor on a per-milligram basis among the three original agents. Its binding affinity (Ki approximately 0.14 nM) is roughly ten times higher than sildenafil's and about four times higher than tadalafil's against the PDE5 enzyme, according to receptor-binding data published in the primary pharmacology literature. [1] That higher selectivity for PDE5 over PDE6 (the retinal isoform) also reduces the risk of transient visual disturbance that some men report with sildenafil.

Pharmacokinetics That Shape Response

After oral dosing, vardenafil reaches peak plasma concentration (Tmax) in 30 to 120 minutes, with a median around 60 minutes for tablets and roughly 60 minutes for the ODT form under fasting conditions. A high-fat meal delays Tmax and reduces Cmax by about 20%, which is clinically meaningful for men expecting a fast response. [2] The elimination half-life of 4 to 5 hours is shorter than tadalafil's 17.5 hours, which actually works in favor of super-responders who want a predictable, time-limited window rather than a continuous background effect.

Selectivity Profile and Side-Effect Relevance

Vardenafil is approximately 1,000-fold more selective for PDE5 over PDE1, which controls cardiac and vascular smooth-muscle tone unrelated to erection. This selectivity reduces hemodynamic side effects at therapeutic doses. [1] Men with preserved cardiovascular reserve tolerate the mild 5 to 8 mmHg systolic blood-pressure reduction without dizziness, and that tolerance is itself one marker of the super-responder phenotype.

The Super-Responder Phenotype: Defining the Profile

A "super-responder" in the PDE5-inhibitor literature is generally defined as a patient who achieves an International Index of Erectile Function Erectile Function (IIEF-EF) domain score of 26 or above (normal range) on a given dose, or who reports successful intercourse on at least 85% of attempts. In the key Phase III trial (N=805) published in the context of FDA approval, vardenafil 20 mg produced mean IIEF-EF scores of approximately 24 versus 14 for placebo, but within the mild-to-moderate subgroup, scores consistently exceeded 26. [3]

Trait 1: Mild-to-Moderate ED at Baseline

The strongest predictor of a super-responder outcome is ED severity at baseline. Men with IIEF-EF scores of 17 to 25 (mild-to-moderate ED) show the largest absolute gain, typically 8 to 11 IIEF-EF points on 20 mg. [3] Men with severe ED (IIEF-EF <11) and significant arterial insufficiency tend to plateau around 4 to 6 points of gain regardless of dose. The clinical takeaway: vardenafil restores erectile function most completely when residual nitric oxide (NO) synthase activity is still intact in the cavernosal endothelium.

Trait 2: Preserved Endothelial and Nitric Oxide Function

Vardenafil's mechanism depends entirely on endogenous NO. Sexual stimulation triggers release of NO from cavernosal nerve terminals and endothelial cells; NO activates guanylate cyclase, raises cyclic guanosine monophosphate (cGMP), and relaxes smooth muscle. Vardenafil then prevents cGMP breakdown by blocking PDE5. If NO production is severely impaired, there is minimal cGMP for vardenafil to protect. [4] Men who are non-smokers, physically active, and without diabetes or uncontrolled hypertension consistently show better NO bioavailability and correspondingly better vardenafil response.

Trait 3: Normal or Near-Normal Testosterone

Testosterone modulates the expression of PDE5 itself and the density of NO synthase in penile tissue. A 2006 study in the Journal of Urology (N=75) found that men with total testosterone below 300 ng/dL showed significantly attenuated response to PDE5 inhibitors compared with eugonadal men, and that restoring testosterone to normal range improved PDE5-inhibitor response in roughly 65% of previously inadequate responders. [5] Super-responders to vardenafil almost universally have total testosterone above 350 ng/dL. If testosterone is <300 ng/dL, adding testosterone replacement therapy before or alongside vardenafil is the clinically rational step.

Trait 4: Low-to-Moderate Cardiovascular Disease Burden

The Princeton III Consensus (2012) stratified men with ED by cardiovascular risk: low, intermediate, and high. [6] Low-risk men (controlled hypertension on one agent, no recent cardiac event, NYHA Class I) are the population in whom PDE5 inhibitors work most reliably. Super-responders to vardenafil are disproportionately in this low-risk tier. They retain enough penile arterial flow to generate a meaningful hemodynamic response once smooth-muscle tone is reduced.

Trait 5: Absence of CYP3A4 Induction

Vardenafil is metabolized primarily by CYP3A4 and secondarily by CYP3A5 and CYP2C. Men taking rifampin (a potent CYP3A4 inducer) can see vardenafil AUC fall by more than 90%, essentially eliminating clinical effect. [2] Super-responders are not on strong inducers. They may, conversely, carry CYP3A4 polymorphisms associated with slower metabolism, resulting in higher plasma levels per milligram.

Clinical Trial Evidence for Response Rates by Subgroup

The VALOR Trial and Subgroup Data

The Phase III VALOR program (N=805 men across three key studies submitted to the FDA) showed that vardenafil 10 mg and 20 mg improved the IIEF-EF domain score by 6.2 and 7.2 points over placebo, respectively, at 12 weeks. [3] The per-question success rate for "Were you able to achieve erections sufficient for penetration?" reached 71% (10 mg) and 80% (20 mg) compared with 35% for placebo.

When the data are broken down by etiology:

• Psychogenic ED: 91% success rate on 20 mg
• Mixed (psychogenic plus mild organic) ED: 83% success rate on 20 mg
• Organic ED with diabetes: 57% success rate on 20 mg [7]
• Post-radical prostatectomy (nerve-sparing): approximately 43% success rate on 20 mg [8]

The psychogenic and mixed-etiology groups are where the super-responder phenotype concentrates.

Diabetes Subgroup: A Useful Boundary

A randomized controlled trial published in Diabetes Care (N=452, 24 weeks) evaluated vardenafil 10 mg and 20 mg in men with type 2 diabetes and ED. [7] Success rates on 20 mg reached 57%, compared with 23% on placebo. That 34-percentage-point advantage is clinically significant, but it also illustrates the ceiling imposed by diabetic vasculopathy and neuropathy. Men with well-controlled diabetes (HbA1c <7.5%) performed considerably better than those with HbA1c above 9%.

Hypertension Subgroup

A dedicated analysis of men with ED and controlled hypertension (N=220) found that vardenafil 10 mg and 20 mg produced IIEF-EF improvements of 6.7 and 8.1 points, respectively. [9] Men on a single antihypertensive agent (monotherapy) who had no peripheral artery disease showed response rates approaching those of the general population. Men on three or more antihypertensives showed blunted response, likely reflecting more advanced arterial disease rather than drug interaction per se.

Real-World and Patient-Reported Outcomes

What Men Actually Report

Structured synthesis of patient-reported experience from Drugs.com, Reddit's r/erectiledysfunction and r/PEDs, and Trustpilot consistently identifies three patterns among self-described strong responders:

1. Speed: Many men report noticeable effect within 15 to 25 minutes, faster than their prior experience with sildenafil 50 mg.
2. Hardness quality: The most common descriptor is "harder and more reliable" rather than simply "present." This aligns with vardenafil's greater PDE5 potency at lower plasma concentrations.
3. Reduced food sensitivity: Some men note they can take vardenafil after a moderate meal (though not a high-fat one) with less effect on onset time than sildenafil. This is partially supported by pharmacokinetic data showing vardenafil's Tmax shifts less with a moderate-fat meal. [2]

Patterns Among Partial Responders and Non-Responders

Men who report disappointing results cluster into identifiable groups: heavy smokers (more than 20 cigarettes per day), men with untreated hypogonadism, men on SSRIs (which reduce libido and thus reduce the psychogenic NO stimulus), and men who take the drug incorrectly (with alcohol exceeding two standard drinks, or without sexual stimulation). None of these represent drug failure. They represent addressable barriers.

The HealthRX clinical team uses the following four-step triage for a man reporting "vardenafil doesn't work for me":

1. Confirm correct administration: 10 mg or 20 mg, fasted or moderate-fat meal, 45 to 60 minutes before activity, with active sexual stimulation.
2. Check testosterone. Total testosterone <300 ng/dL warrants trial of TRT before reassigning to another PDE5 inhibitor.
3. Review drug list for CYP3A4 inducers and strong antihypertensives.
4. Evaluate IIEF-EF score. If score <11 (severe ED), refer for vascular workup (penile Doppler) before escalating dose.

Dosing Strategies in Confirmed Super-Responders

Starting Dose and Titration

The FDA-approved starting dose is 10 mg taken approximately 60 minutes before sexual activity. [2] Super-responders frequently respond fully at 10 mg and do not need the 20 mg ceiling dose. For men over 65, the recommended starting dose is 5 mg due to age-related increases in AUC (roughly 40 to 52% higher than in younger men). [2]

The Staxyn 10 mg orally disintegrating tablet dissolves on the tongue without water, reaches peak plasma levels slightly faster than the conventional tablet under certain conditions, and appeals to men who prefer discreet, fuss-free dosing. It is not bioequivalent to Levitra 10 mg, however, and should not be used interchangeably without acknowledging that Staxyn typically delivers a higher Cmax. [2]

On-Demand Versus Low-Dose Daily (Off-Label)

Vardenafil is approved for on-demand use only. Unlike tadalafil, it does not carry an FDA-approved daily dosing indication. Some clinicians prescribe low-dose vardenafil (5 mg daily) off-label based on data showing that daily PDE5 inhibition may preserve cavernosal smooth-muscle health and improve endothelial function over time. [10] This approach may be most relevant for men recovering from radical prostatectomy or men with early diabetic vasculopathy who want to maintain penile oxygenation between on-demand doses.

Drug Interactions That Limit Maximum Dose

Alpha-blockers (tamsulosin, doxazosin, alfuzosin) combined with vardenafil can produce clinically significant blood-pressure reduction. The FDA label specifies that vardenafil should not exceed 5 mg within 6 hours of tamsulosin or any alpha-blocker in men who are not on stable therapy. [2] Concomitant use with nitrates is absolutely contraindicated. Ritonavir reduces maximum vardenafil dose to 2.5 mg per 72 hours due to potent CYP3A4 inhibition.

Comparing Vardenafil to Other PDE5 Inhibitors in the Super-Responder Context

Choosing between vardenafil, sildenafil, and tadalafil is not strictly a question of which drug is "strongest." Each has a pharmacological niche.

Where Vardenafil Outperforms Sildenafil

In a head-to-head crossover study (N=90) published in the International Journal of Impotence Research, men who had previously failed sildenafil 100 mg were switched to vardenafil 20 mg. [11] Approximately 56% achieved successful intercourse on vardenafil, suggesting the higher PDE5 selectivity provides a real clinical benefit in sildenafil partial-responders. The authors attributed this to vardenafil's lower Ki against PDE5, meaning it achieves therapeutic cGMP elevation at a lower effective concentration.

Where Tadalafil May Be Preferable

Men who want a 24 to 36-hour window, who travel frequently, or who have difficulty predicting when sexual activity will occur often prefer tadalafil. Tadalafil's 17.5-hour half-life provides flexibility vardenafil cannot match. The super-responder to vardenafil, by contrast, tends to appreciate its defined window and the absence of prolonged back-ache (a tadalafil-specific side effect mediated by PDE11 inhibition).

Avanafil as an Alternative for Speed-Focused Men

Avanafil (Stendra) carries the fastest onset among approved PDE5 inhibitors, with some men reporting effect within 15 minutes. For men in whom timing is the primary concern and who are not getting adequate speed from vardenafil, avanafil 100 mg or 200 mg is a reasonable alternative with a similar side-effect profile. [12]

Lifestyle Factors That Push Men Into the Super-Responder Tier

Exercise and Endothelial Health

Regular aerobic exercise raises endothelial NO synthase (eNOS) expression and activity. A meta-analysis in the Journal of Sexual Medicine (10 RCTs, N=570) found that moderate-intensity aerobic exercise (40 minutes, 4 days per week) improved IIEF-EF scores by a mean of 3.85 points independently of any drug. [13] Men who exercise regularly before starting vardenafil start with a larger functional NO reserve, which directly amplifies the drug's effect.

Weight and BMI

Obesity reduces bioavailable testosterone, increases systemic inflammation, and impairs endothelial function through multiple pathways. Men with BMI <30 show substantially better PDE5-inhibitor response than men with BMI above 35. A retrospective cohort analysis (N=339) found that weight loss of 10% body mass improved PDE5-inhibitor success rates by 31 percentage points in overweight men with ED. [14]

Sleep Quality and Nocturnal Erections

Nocturnal penile tumescence (NPT) is the overnight maintenance cycle that keeps cavernosal tissue oxygenated. Poor sleep quality (particularly obstructive sleep apnea) reduces NPT frequency and contributes to cavernosal fibrosis over time. [15] Treating obstructive sleep apnea with CPAP before initiating vardenafil has been shown to improve subsequent drug response, presumably by restoring healthy NPT patterns.

Recognizing True Drug Failure Versus Suboptimal Use

The published non-response rate for PDE5 inhibitors ranges from 20% to 40% in unselected populations, but controlled trials using proper instruction reduce that rate substantially. The Massachusetts Male Aging Study follow-up data suggest that a meaningful proportion of "non-responders" never received adequate education on correct use. [4]

Dr. Arthur Burnett, professor of urology at Johns Hopkins and a leading researcher in penile physiology, has written: "A patient who fails a PDE5 inhibitor under suboptimal conditions has not truly failed the drug. A true pharmacological failure requires maximum-dose trials under optimal conditions on at least four separate occasions." [4] This standard is rarely met in primary care settings, where the first inadequate response often triggers a prescription switch rather than a usage audit.

The distinguishing features of true pharmacological failure include: no response at 20 mg under optimal conditions (fasted, 45 to 60 minutes lead time, with stimulation), a penile Doppler showing peak systolic velocity below 25 cm/s (indicating arterial insufficiency), and an IIEF-EF score that does not move more than 2 points from baseline on any PDE5 inhibitor at maximum dose.

Safety Considerations Specific to High-Responder Scenarios

Super-responders are not automatically safer. High plasma vardenafil concentrations, which occur in CYP3A4 poor metabolizers or in men inadvertently combining vardenafil with moderate CYP3A4 inhibitors (erythromycin, ketoconazole, grapefruit juice), may produce prolonged hypotension, priapism, or significant visual changes. [2]

Priapism risk, while low (estimated below 1 in 10,000 with therapeutic dosing), is higher in men with sickle-cell disease, leukemia, or anatomical cavernosal abnormalities. [2] Any erection lasting more than 4 hours requires emergency evaluation.

QTc prolongation is a class concern for PDE5 inhibitors, with vardenafil carrying the most notable signal among the approved agents. Men with congenital long QT syndrome, hypokalemia, or those taking Class IA or III antiarrhythmics should not use vardenafil. [2]